查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1447073

到 2030 年结直肠癌市场预测：按方式、最终用户和地区进行的全球分析

Colorectal Cancer Market Forecasts to 2030 - Global Analysis By Modility (Diagnosis Type, Therapy Type and Other Modilities), End User(Hospitals, Diagnostic and Research Laboratories and Other End Users) and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球大肠癌市场规模为 196 亿美元，预计预测期内复合年增长率为 5.30%，到 2030 年将达到 281 亿美元。

大肠直肠癌是一种在结肠和直肠中发生的恶性，结肠和直肠是消化器官系统的一部分。它通常始于称为息肉的小型非癌性生长，并随着时间的推移逐渐转变为癌症。症状包括饮食习惯改变、血便、腹部不适和体重意外减轻。大肠镜检查等筛检测试可以帮助在息肉癌变之前发现并切除息肉，从而增加早期发现和成功治疗的机会。

根据世界卫生组织（WHO）统计，大肠直肠癌的发生率位居癌症第三位，2020年全球约有193万人患有大肠癌，到2030年，全球大肠癌病例数还将增加。预计人数将增加约70%。根据国际癌症研究机构和 GLOBOCAN 的数据，预计 2020 年亚洲大肠癌发生率约为 1,009,400 例。

联合研究工作

合作研究是促进研究人员、医疗机构和製药公司之间协同效应的重要驱动力。这些合作能够共用资源、专业知识和资料，以加速创新治疗方法和诊断工具的发现和发展。透过共用见解和最佳实践，研究人员正在发现新的生物标记、治疗标靶和治疗方法，最终改善患者的治疗结果。此外，合作研究促进了调查方法和临床试验通讯协定的标准化，从而产生稳健可靠的资料。

目前治疗方法的效果有限

目前大肠直肠癌市场上的治疗方法效果有限是由多种因素造成的。存在手术、化疗和标靶治疗，但它们具有显着的副作用，并且往往并非对所有患者有效，特别是那些患有晚期疾病或具有某些基因突变的患者。随着时间的推移，抗药性会产生并降低治疗效果。大肠直肠癌的复杂性和异质性也对开发针对个别患者的有效治疗方法提出了挑战。此外，目前的情况突显需要继续研究和开发新的治疗方法以改善大肠直肠癌患者的预后。

生物标誌物开发

生物标记为大肠直肠癌患者的早期检测、准确诊断、预后预测和治疗效果监测提供了可能。基于生物标记的检测可以透过识别适当的患者群体、加速药物开发和降低成本来简化临床试验。将生物标记纳入常规筛检计画有可能提高大肠癌筛检的效率、减轻医疗保健系统的负担并改善资源分配。此外，大肠直肠癌生物标记的开发为推动精准医疗和改善这种常见恶性的治疗提供了一条有希望的途径。

生物相似药的出现

生物相似药的出现构成了重大威胁，因为它们有可能以较低的成本提供相同的功效。生物相似药是一种与已核准的生物製药相似的产品，一旦原厂产品的专利到期即可进入市场。因此，生物相似药为患者提供了更便宜的治疗选择。由于生物相似药可以以较低的价格提供类似的功效，因此它们可能会威胁原厂生物製药的市场力量，并减少现有大肠直肠癌治疗的市场占有率。这种竞争可能会压低价格，迫使品牌药厂调整其定价策略，否则将面临市场占有率下降。

COVID-19 的影响：

COVID-19 大流行以多种方式对大肠癌市场产生了重大影响。由于医疗保健资源的排除和重新分配而导致筛检和诊断程序的延迟，导致早期检测减少，并可能导致晚期诊断。治疗的取得和依从性也受到影响，导致治疗週期和病患管理中断。供应链中断和临床试验延迟阻碍了新治疗方法的开发和可用性。儘管有这些挑战，远端医疗和创新护理服务模式的使用已经出现，有助于减轻一些影响。这突显出需要有弹性的医疗保健系统，即使在危机情况下也能管理癌症治疗。

预计在预测期内最大的治疗类型

由于治疗方法的进步，治疗类型正在显着增长。这一增长是由越来越多地采用标靶治疗、免疫疗法和联合治疗推动的，与传统化疗相比，这些疗法可提高疗效并减少副作用。生物标记测试等精准医学方法的发展使得针对每个患者的基因谱量身定制更个性化的治疗策略成为可能。此外，正在进行的探索新治疗药物和治疗方法组合的研究和临床试验也正在推动这一领域的创新和扩张。

诊断和研究测试产业预计在预测期内复合年增长率最高

由于诊断技术的进步和对早期检测的兴趣的增加，诊断和研究实验室领域正在经历显着的增长。这些实验室在分子测定和液态切片等创新诊断测试的开发和检验中发挥关键作用，这些测试在结直肠癌生物标记的检测中提供了更高的灵敏度和特异性。旨在阐明结直肠癌进展的潜在机制的研究投资的增加正在刺激对检测服务的需求。此外，人工智慧和机器学习演算法在资料分析中的整合正在提高这些实验室诊断过程的准确性和效率。

比最大的地区

由于人们对早期检测和筛检计划重要性的认识不断提高、诊断技术的进步以及人口老化，北美结直肠癌市场正在经历强劲增长。医疗保健服务的改善和有利的报销政策有助于市场扩张。製药公司也积极开发创新治疗方法和治疗方法，进一步促进成长。总体而言，北美地区继续发挥关键作用，持续努力改善患者治疗结果并降低死亡率。

复合年增长率最高的地区：

由于生活方式改变、饮食习惯和人口老化等因素导致大肠直肠癌发病率上升，亚太地区大肠直肠癌市场正在经历显着增长。提高认识宣传活动、改进筛检计划以及诊断技术的进步正在促进早期发现和治疗。该地区许多国家不断扩大的医疗基础设施和不断上升的医疗成本正在推动大肠癌治疗的需求。此外，政府、医疗保健组织和製药公司之间为解决大肠癌负担而进行的合作也在推动亚太地区市场成长方面发挥着至关重要的作用。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球大肠直肠癌市场：依方式分类

  • 诊断类型
    • 免疫组织化学
    • 粪便检验
    • 软式乙状结肠镜检查
    • 大肠镜检查
    • CEA测试
    • 其他诊断类型
  • 治疗类型
    • 化疗
      • 烷化剂
      • 抗代谢物
      • 其他化疗
    • 免疫疗法
      • Panitumumab
      • Cetuximab
      • Bevacizumab
      • 其他免疫疗法
    • 其他治疗方法
  • 影像类型
    • 电脑断层扫描 (CT)
    • 磁振造影(MRI)
    • 其他图像类型
  • 其他方式

第六章全球大肠直肠癌市场：依最终用户分类

  • 医院
  • 诊断和研究机构
  • 其他最终用户

第七章全球大肠直肠癌市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第八章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第九章 公司简介

  • Abbott Diagnostics
  • Alaunos Therapeutics Inc
  • Alere
  • Beckman Coulter
  • Bristol-Myers Squibb Co,
  • Clinical Genomics
  • Debiopharm Group
  • F-Hoffmann-La Roche Ltd,
  • Immunovative Therapies Ltd
  • Iovance Biotherapeutics,
  • Replimune Group
  • Transgene SA
  • Turnstone Biologics Inc.
  • Vaccinogen BD
Product Code: SMRC25334

According to Stratistics MRC, the Global Colorectal Cancer Market is accounted for $19.60 billion in 2023 and is expected to reach $28.10 billion by 2030 growing at a CAGR of 5.30% during the forecast period. Colorectal cancer is a malignant tumor that develops in the colon or rectum, which are parts of the digestive system. It usually begins as small, noncancerous growths called polyps that can gradually transform into cancer over time. Symptoms may include changes in bowel habits, blood in the stool, abdominal discomfort, and unintended weight loss. Screening tests such as colonoscopies can help detect and remove polyps before they become cancerous, increasing the chances of early detection and successful treatment.

According to the World Health Organization (WHO), colorectal cancer is the third most prevalent form of cancer, with ~1.93 million global cases in 2020, and an increase of ~70% in colorectal cancer cases worldwide is expected by 2030. According to the International Agency for Research on Cancer & GLOBOCAN, the estimated incidence of colorectal cancer in Asia reported ~1,009,400 new cases in 2020.

Market Dynamics:

Driver:

Collaborative research efforts

Collaborative research efforts serve as a significant driver by fostering synergy among researchers, healthcare institutions, and pharmaceutical companies. These collaborations enable the pooling of resources, expertise, and data, expediting the discovery and development of innovative treatments and diagnostic tools. By sharing insights and best practices, researchers are uncovering novel biomarkers, therapeutic targets, and treatment modalities, ultimately enhancing patient outcomes. Furthermore, collaborative efforts promote the standardization of research methodologies and clinical trial protocols, ensuring robust and reliable data generation.

Restraint:

Limited efficacy of current treatments

The limited efficacy of current treatments in the colorectal cancer market arises due to several factors. While surgeries, chemotherapy, and targeted therapies exist, they often come with significant side effects and may not be effective for all patients, particularly those with advanced stages of the disease or certain genetic mutations. Drug resistance can develop over time, reducing the effectiveness of treatments. The complexity and heterogeneity of colorectal cancer also pose challenges in developing effective treatments tailored to individual patients. Additionally, the current landscape highlights the need for continued research and development of novel therapies to improve outcomes for colorectal cancer patients.

Opportunity:

Biomarker development

Biomarkers offer the potential for early detection, accurate diagnosis, prognosis prediction, and monitoring of treatment response in colorectal cancer patients. Biomarker-based assays could streamline clinical trials by identifying suitable patient populations, expediting drug development, and reducing costs. The integration of biomarkers into routine screening programs could enhance the efficiency of colorectal cancer detection, potentially reducing the burden on healthcare systems and improving resource allocation. Furthermore, biomarker development in colorectal cancer represents a promising avenue for advancing precision medicine and improving the management of this prevalent malignancy.

Threat:

Emergence of biosimilars

The emergence of biosimilars poses a significant threat due to their potential to offer comparable efficacy at lower costs. Biosimilars are highly similar versions of already-approved biologic drugs that can enter the market once the patents on the original drugs expire. As a result, they provide patients with more affordable treatment options. This threatens the market dominance of originator biologics, as biosimilars can offer similar benefits at reduced prices, potentially leading to market share erosion for established colorectal cancer treatments. This competition may drive down prices, forcing original drug manufacturers to adjust their pricing strategies or face decreased market share.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the colorectal cancer market on multiple fronts. Delayed screenings and diagnostic procedures due to lockdowns and healthcare resource reallocations led to a decline in early detections, potentially resulting in advanced-stage diagnoses. Treatment access and adherence were also affected, causing disruptions in therapy cycles and patient management. Supply chain interruptions and clinical trial delays hampered the development and availability of new therapies. Despite these challenges, telemedicine utilization and innovative care delivery models emerged to mitigate some of the impacts, emphasizing the need for resilient healthcare systems to manage cancer care during crises.

The therapy type segment is expected to be the largest during the forecast period

The therapy type segment has shown significant growth due to advancements in treatment modalities. This growth can be attributed to the increasing adoption of targeted therapies, immunotherapies, and combination treatments, which offer improved efficacy and reduced side effects compared to traditional chemotherapy. The development of precision medicine approaches, such as biomarker testing, has allowed for more personalized treatment strategies tailored to individual patients' genetic profiles. Additionally, ongoing research efforts and clinical trials exploring novel therapeutic agents and treatment combinations continue to drive innovation and expansion within this segment.

The diagnostic and research laboratories segment is expected to have the highest CAGR during the forecast period

The Diagnostic and Research Laboratories segment in has experienced substantial growth due to advancements in diagnostic technologies and an increased focus on early detection. These laboratories play a crucial role in the development and validation of innovative diagnostic tests, such as molecular assays and liquid biopsies, which offer higher sensitivity and specificity in detecting colorectal cancer biomarkers. Rising investments in research aimed at understanding the underlying mechanisms of colorectal cancer progression which have fuelled demand for laboratory services. Additionally, the integration of artificial intelligence and machine learning algorithms in data analysis has enhanced the accuracy and efficiency of diagnostic processes in these laboratories.

Region with largest share:

North American region has seen robust growth in the colorectal cancer market, driven by increasing awareness about the importance of early detection and screening programs, advancements in diagnostic technologies, and a growing aging population. Improved access to healthcare services and favorable reimbursement policies have contributed to the expansion of the market. Pharmaceutical companies have also been actively developing innovative treatments and therapies, further fueling growth. Overall, the North American region continues to be a key player, with sustained efforts towards improving patient outcomes and reducing mortality rates.

Region with highest CAGR:

The Asia-Pacific region has witnessed significant growth in the colorectal cancer market due to rising incidence rates of colorectal cancer, attributed to factors such as lifestyle changes, dietary habits, and an aging population. Increased awareness campaigns, improved screening programs, and advancements in diagnostic technologies have facilitated early detection and treatment. Expanding healthcare infrastructure and increasing healthcare expenditures across many countries in the region have fueled the demand for colorectal cancer treatments and therapies. Additionally, collaborations between governments, healthcare organizations, and pharmaceutical companies to address the burden of colorectal cancer have also played a pivotal role in driving market growth in the Asia-Pacific region.

Key players in the market

Some of the key players in Colorectal Cancer market include Abbott Diagnostics, Alaunos Therapeutics Inc, Alere, Beckman Coulter, Bristol-Myers Squibb Co, Clinical Genomics, Debiopharm Group, F-Hoffmann-La Roche Ltd, Immunovative Therapies Ltd, Iovance Biotherapeutics, Replimune Group, Transgene SA , Turnstone Biologics Inc. and Vaccinogen BD.

Key Developments:

In August 2023, Redcliffe Labs has partnered with Abbott India to launch Clinical Decision Support (CDS), also known as AlinIQ, which is powered by unique technologies such as Big Data Engines and Artificial Intelligence (AI). This game-changing advancement intends to revolutionise healthcare by providing potential solutions to improve patient care and ease.

In March 2023, Scailyte AG announced that it entered into collaboration with Turnstone Biologics to discover signature biomarkers predictive of clinical responses to tumor-infiltrating lymphocyte (TIL) therapy by applying ScaiVision, Scailyte's best-in-class single-cell sequencing analytical platform.

Modilities Covered:

  • Diagnosis Type
  • Therapy Type
  • Imaging Type
  • Other Modilities

End Users Covered:

  • Hospitals
  • Diagnostic and Research Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Colorectal Cancer Market, By Modility

  • 5.1 Introduction
  • 5.2 Diagnosis Type
    • 5.2.1 Immunohistochemistry
    • 5.2.2 Stool Test
    • 5.2.3 Flexible Sigmoidoscopy
    • 5.2.4 Colonoscopy
    • 5.2.5 CEA Test
    • 5.2.6 Other Diagnosis Types
  • 5.3 Therapy Type
    • 5.3.1 Chemotherapy
      • 5.3.1.1 Alkylating Agent
      • 5.3.1.2 Antimetabolites
      • 5.3.1.3 Other Chemotherapies
    • 5.3.2 Immunotherapy
      • 5.3.2.1 Panitumumab
      • 5.3.2.2 Cetuximab
      • 5.3.2.3 Bevacizumab
      • 5.3.2.4 Other Immunotherapies
    • 5.3.3 Other Therapy Types
  • 5.4 Imaging Type
    • 5.4.1 Computed Tomography (CT)
    • 5.4.2 Magnetic Resonance Imaging (MRI)
    • 5.4.3 Other Imaging Types
  • 5.5 Other Modilities

6 Global Colorectal Cancer Market, By End User

  • 6.1 Introduction
  • 6.2 Hospitals
  • 6.3 Diagnostic and Research Laboratories
  • 6.4 Other End Users

7 Global Colorectal Cancer Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Abbott Diagnostics
  • 9.2 Alaunos Therapeutics Inc
  • 9.3 Alere
  • 9.4 Beckman Coulter
  • 9.5 Bristol-Myers Squibb Co,
  • 9.6 Clinical Genomics
  • 9.7 Debiopharm Group
  • 9.8 F-Hoffmann-La Roche Ltd,
  • 9.9 Immunovative Therapies Ltd
  • 9.10 Iovance Biotherapeutics,
  • 9.11 Replimune Group
  • 9.12 Transgene SA
  • 9.13 Turnstone Biologics Inc.
  • 9.14 Vaccinogen BD

List of Tables

  • Table 1 Global Colorectal Cancer Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Colorectal Cancer Market Outlook, By Modality (2021-2030) ($MN)
  • Table 3 Global Colorectal Cancer Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 4 Global Colorectal Cancer Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 5 Global Colorectal Cancer Market Outlook, By Stool Test (2021-2030) ($MN)
  • Table 6 Global Colorectal Cancer Market Outlook, By Flexible Sigmoidoscopy (2021-2030) ($MN)
  • Table 7 Global Colorectal Cancer Market Outlook, By Colonoscopy (2021-2030) ($MN)
  • Table 8 Global Colorectal Cancer Market Outlook, By CEA Test (2021-2030) ($MN)
  • Table 9 Global Colorectal Cancer Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 10 Global Colorectal Cancer Market Outlook, By Therapy Type (2021-2030) ($MN)
  • Table 11 Global Colorectal Cancer Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 12 Global Colorectal Cancer Market Outlook, By Alkylating Agent (2021-2030) ($MN)
  • Table 13 Global Colorectal Cancer Market Outlook, By Antimetabolites (2021-2030) ($MN)
  • Table 14 Global Colorectal Cancer Market Outlook, By Other Chemotherapies (2021-2030) ($MN)
  • Table 15 Global Colorectal Cancer Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 16 Global Colorectal Cancer Market Outlook, By Panitumumab (2021-2030) ($MN)
  • Table 17 Global Colorectal Cancer Market Outlook, By Cetuximab (2021-2030) ($MN)
  • Table 18 Global Colorectal Cancer Market Outlook, By Bevacizumab (2021-2030) ($MN)
  • Table 19 Global Colorectal Cancer Market Outlook, By Other Immunotherapies (2021-2030) ($MN)
  • Table 20 Global Colorectal Cancer Market Outlook, By Other Therapy Types (2021-2030) ($MN)
  • Table 21 Global Colorectal Cancer Market Outlook, By Imaging Type (2021-2030) ($MN)
  • Table 22 Global Colorectal Cancer Market Outlook, By Computed Tomography (CT) (2021-2030) ($MN)
  • Table 23 Global Colorectal Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2021-2030) ($MN)
  • Table 24 Global Colorectal Cancer Market Outlook, By Other Imaging Types (2021-2030) ($MN)
  • Table 25 Global Colorectal Cancer Market Outlook, By Other Modalities (2021-2030) ($MN)
  • Table 26 Global Colorectal Cancer Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Colorectal Cancer Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 28 Global Colorectal Cancer Market Outlook, By Diagnostic and Research Laboratories (2021-2030) ($MN)
  • Table 29 Global Colorectal Cancer Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.